Exportació completada — 

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

Infliximab is an anti-tumor necrosis factor monoclonal antibody approved in chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease (CD) and ulcerative colitis (UC). Infliximab pharmacokinetics is variable between...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Passot, Christophe, Mulleman, Denis, Bejan-Angoulvant, Theodora, Aubourg, Alexandre, Willot, Stephanie, Lecomte, Thierry, Picon, Laurence, Goupille, Philippe, Paintaud, Gilles, Ternant, David
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058621/
https://ncbi.nlm.nih.gov/pubmed/27589009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1216741
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars